Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
Type:
Application
Filed:
June 14, 2016
Publication date:
September 29, 2016
Applicant:
Genentech, Inc.
Inventors:
John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben
Abstract: Methods and compositions are provided for treating cancer in patients with a therapeutic combination comprising a therapeutically effective amounts of taselisib and palbociclib, or stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof.
Type:
Application
Filed:
March 24, 2016
Publication date:
September 29, 2016
Applicant:
Genentech, Inc.
Inventors:
Lori Friedman, Michelle Nannini, Deepak Sampath, Jeffrey Wallin
Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
Type:
Application
Filed:
June 16, 2016
Publication date:
September 29, 2016
Applicant:
Genentech, Inc.
Inventors:
Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
Abstract: 2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Type:
Application
Filed:
March 18, 2016
Publication date:
September 22, 2016
Applicant:
Genentech, Inc.
Inventors:
Robert Blake, Paola Di Lello, Jake Drummond, Christine Johanna Heideker, Lorna Kategaya, Till Maurer, Jeremy M. Murray, Chudi Ndubaku, Richard Pastor, Lionel Rouge, Vickie Tsui, Ingrid E. Wertz, Kebing Yu
Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
Type:
Application
Filed:
October 28, 2015
Publication date:
September 22, 2016
Applicants:
GENENTECH, INC., AC IMMUNE S.A.
Inventors:
Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
Abstract: Compounds of the formula I or II: or pharmaceutically acceptable salts thereof, wherein R1 is a group of formula (a), (b), (c); (d) or (e): and m, n, X, Y, R1, R2, R3, R4, Rb and Rc are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
Abstract: Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. The methods provided are based on a set of alleles associated with systemic lupus erythematosus (SLE) risk loci including BLK, TNIP1, PRDM1, JAZF1, UHRF1BP1, IL10, IFIH1, CFB, CEC16A, IL12B and SH2B3 that contribute to SLE risk. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents.
Abstract: The invention is concerned with the compounds of formula I: and salts thereof and other compounds of formulas II-IX as disclosed herein. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formulas I-IX as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain or asthma.
Type:
Application
Filed:
February 12, 2016
Publication date:
September 15, 2016
Applicant:
Genentech, Inc.
Inventors:
Po-wai YUEN, Anthony ESTRADA, Huifen CHEN, Aleksandr KOLESNIKOV, Elisia VILLEMURE, Vishal VERMA, Lan WANG, Daniel SHORE, Steven DO, Matthew VOLGRAF, Baihua HU, Guosheng WU, Xingyu LIN, Aijun LU
Abstract: Biological markers that predict patient responsiveness to B-cell antagonists are provided. Also provided are methods of using such biological markers. In addition, methods for identifying patients suffering from an autoimmune disease, e.g., rheumatoid arthritis, who are not likely to respond to B-cell antagonists are provided, as are methods of treating such patients. Methods for selecting therapeutic agents to treat such patients are also provided.
Type:
Application
Filed:
February 9, 2016
Publication date:
September 15, 2016
Applicant:
Genentech, Inc.
Inventors:
Timothy W. BEHRENS, Kasia OWCZARCZYK, Michael J. TOWNSEND
Abstract: Cell culture media are provided herein as are methods of using the media for cell culture and antibody production from cells. Compositions comprising antibodies and fragments thereof, produced by the methods herein are also provided.
Abstract: The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
Type:
Grant
Filed:
June 18, 2015
Date of Patent:
September 13, 2016
Assignee:
GENENTECH, INC.
Inventors:
Hazel Joan Dyke, Lewis Gazzard, Karen Williams, Huifen Chen, Samuel Kintz, Joy Drobnick, Joseph P. Lyssikatos, Simon Goodacre, Calum Macleod, Charles Ellwood
Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
Type:
Application
Filed:
October 6, 2015
Publication date:
September 8, 2016
Applicant:
GENENTECH, INC.
Inventors:
Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-Yee Chen
Abstract: This invention relates to novel compounds which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer.
Type:
Application
Filed:
May 12, 2016
Publication date:
September 8, 2016
Applicant:
Genentech, Inc.
Inventors:
Marian C. Bryan, Bryan Chan, Francois Diederich, Jennafer Dotson, Emily Hanan, Timothy Heffron, Michael Lainchbury
Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
Type:
Grant
Filed:
October 9, 2013
Date of Patent:
September 6, 2016
Assignee:
Genentech, Inc.
Inventors:
Bing-Yan Zhu, Michael Siu, Steven R. Magnuson, Richard Pastor, He Haiying, Xiao Yisong, Zheng Jifu, Xu Xing, Zhao Junping, Christopher Hurley, Jun Liang, Wendy Liu, Joseph P. Lyssikatos
Abstract: Disclosed are crystalline forms of (R)—N-(4-(3-aminopiperidin-1-yl)-5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)cyclopropanecarboxamide, and salts, solvates, and hydrates thereof, and pharmaceutical compositions, formulations and a process of manufacturing thereof.
Type:
Application
Filed:
February 26, 2016
Publication date:
September 1, 2016
Applicants:
Genentech, Inc., Array Biopharma Inc.
Inventors:
Jeffrey Stults, Christopher M. Lindemann, Keith L. Spencer, Weidong Liu, Joseph Lubach
Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
Type:
Application
Filed:
January 26, 2016
Publication date:
September 1, 2016
Applicant:
Genentech, Inc.
Inventors:
Jan Marik, Joseph P. Lyssikatos, Simon Williams
Abstract: Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using an antagonist of FGFR signaling.
Type:
Application
Filed:
March 6, 2014
Publication date:
September 1, 2016
Applicant:
Genentech, Inc.
Inventors:
Robert L. YAUCH, Xiaofen YE, Avi ASHKENAZI
Abstract: The present invention provides methods for purifying a polypeptide comprising a CH2/CH3 region, comprising binding the polypeptide to Protein A and eluting with a pH gradient starting at a low pH.
Type:
Grant
Filed:
September 1, 2010
Date of Patent:
August 30, 2016
Assignee:
Genentech, Inc.
Inventors:
Arick Brown, Christopher J. Dowd, Asha Nandini Radhamohan